A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

Steven G. Potkin*, Georges M. Gharabawi, Andrew J. Greenspan, Ramy Mahmoud, Colette Kosik-Gonzalez, Marcia F.T. Rupnow, Cynthia A. Bossie, Michael Davidson, Victoria Burtea, Young Zhu, Jintendra K. Trivedi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization. Methods: This international, randomized, double-blind study included a 2-week monotherapy phase followed by a 4-week additive therapy phase. Recently exacerbated patients with schizophrenia or schizoaffective disorder (DSM-IV) were randomized (2:2:1) to risperidone (n = 153), quetiapine (n = 156), or placebo (n = 73). Target doses were 4 or 6 mg/day of risperidone and 400 or 600 mg/day of quetiapine by day 5, with the ability to increase to 600 or 800 mg/day of quetiapine on day 8. The main outcome measures were the total Positive and Negative Syndrome Scale (PANSS) and need for additional psychotropic medications. Results: Monotherapy Phase: The combined atypical antipsychotic group (n = 308) reached borderline superiority to placebo (n = 71) at the 2-week endpoint on mean change in total PANSS score (- 24.1 ± 1.2 and - 20.2 ± 2.0, respectively; p = 0.067). The change in the atypical group was driven by the improvement with risperidone (- 27.7 ± 1.5 vs. - 20.2 ± 2.0 with placebo, p < 0.01; and vs. - 20.5 ± 1.5 with quetiapine, p < 0.01); the improvement with quetiapine was similar to placebo, p = 0.879. Results were similar on other efficacy endpoints. Additive Therapy Phase: Additional psychotropics were prescribed to fewer (p < 0.01) risperidone (36%) than quetiapine (53%) or placebo patients (59%). The overall discontinuation rate was 18%, 26%, and 38%, respectively. Risperidone, compared with placebo, was associated with more parkinsonism, akathisia, plasma prolactin changes, and weight gain; while quetiapine was associated with more somnolence, sedation, dizziness, constipation, tachycardia, thyroid dysregulation, and weight gain. Conclusion: While the combined atypical antipsychotic group did not experience greater improvements than the placebo group, risperidone, but not quetiapine, was significantly superior in all measured domains to placebo in the management of recently exacerbated hospitalized patients with schizophrenia or schizoaffective disorder, with no unexpected tolerability findings.

Original languageEnglish
Pages (from-to)254-265
Number of pages12
JournalSchizophrenia Research
Volume85
Issue number1-3
DOIs
StatePublished - Jul 2006
Externally publishedYes

Keywords

  • Acute exacerbation
  • Inpatients
  • Polypharmacy
  • Quetiapine
  • Risperidone
  • Schizophrenia

Fingerprint

Dive into the research topics of 'A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization'. Together they form a unique fingerprint.

Cite this